Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.

S Stintzing; V Heinemann; LF von Weikersthal; M Fuchs; F Kaiser; K Heinrich; DP Modest; RD Hofheinz; T Decker; Armin Gerger; S Angermeier; H Rumpold; L Ohler; B Gruenberger; D Niedersuess-Beke; T Winder; J Trojan; GW Prager; A Baraniskin; S Klein-Scory

Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.

S Stintzing
, V Heinemann
, LF von Weikersthal
, M Fuchs
, F Kaiser
, K Heinrich
, DP Modest
, RD Hofheinz
, T Decker
, Armin Gerger
, S Angermeier
, H Rumpold
, L Ohler
, B Gruenberger
, D Niedersuess-Beke
, T Winder
, J Trojan
, GW Prager
, A Baraniskin
, S Klein-Scory

Division of Oncology

Research output: Contribution to journal › Conference abstract

17 Citations (Web of Science)

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	41
Issue number	16
Publication status	Published - 1 Jun 2023
Event	59th Annual Meeting of the American Society of Clinical Oncology - Chicago, United States Duration: 2 Jun 2023 → 6 Jun 2023

Branches of science

302 Clinical Medicine

Links

Web of Science

Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.
Stintzing, S. (Author), Heinemann, V. (Author), von Weikersthal, L. (Author), Fuchs, M. (Author), Kaiser, F. (Author), Heinrich, K. (Author), Modest, D. (Author), Hofheinz, R. (Author), Decker, T. (Author), Gerger, A. (Author), Angermeier, S. (Author), Rumpold, H. (Author), Ohler, L. (Author), Gruenberger, B. (Author), Niedersuess-Beke, D. (Author), Winder, T. (Author), Trojan, J. (Author), Prager, G. (Author), Baraniskin, A. (Author) & Klein-Scory, S. (Author)
2023
Activity: Talk, presentation or poster › Poster

Cite this

Stintzing, S., Heinemann, V., von Weikersthal, LF., Fuchs, M., Kaiser, F., Heinrich, K., Modest, DP., Hofheinz, RD., Decker, T., Gerger, A., Angermeier, S., Rumpold, H., Ohler, L., Gruenberger, B., Niedersuess-Beke, D., Winder, T., Trojan, J., Prager, GW., Baraniskin, A., & Klein-Scory, S. (2023). Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC. Journal of Clinical Oncology, 41(16).

@article{7eedbc0675bb4f25a04e54c715bcf3e4,

title = "Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.",

author = "S Stintzing and V Heinemann and \{von Weikersthal\}, LF and M Fuchs and F Kaiser and K Heinrich and DP Modest and RD Hofheinz and T Decker and Armin Gerger and S Angermeier and H Rumpold and L Ohler and B Gruenberger and D Niedersuess-Beke and T Winder and J Trojan and GW Prager and A Baraniskin and S Klein-Scory",

year = "2023",

month = jun,

day = "1",

language = "English",

volume = "41",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "16",

note = "59th Annual Meeting of the American Society of Clinical Oncology, ASCO 59 ; Conference date: 02-06-2023 Through 06-06-2023",

}

Stintzing, S, Heinemann, V, von Weikersthal, LF, Fuchs, M, Kaiser, F, Heinrich, K, Modest, DP, Hofheinz, RD, Decker, T, Gerger, A, Angermeier, S, Rumpold, H, Ohler, L, Gruenberger, B, Niedersuess-Beke, D, Winder, T, Trojan, J, Prager, GW, Baraniskin, A & Klein-Scory, S 2023, 'Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.', Journal of Clinical Oncology, vol. 41, no. 16.

TY - JOUR

T1 - Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.

AU - Stintzing, S

AU - Heinemann, V

AU - von Weikersthal, LF

AU - Fuchs, M

AU - Kaiser, F

AU - Heinrich, K

AU - Modest, DP

AU - Hofheinz, RD

AU - Decker, T

AU - Gerger, Armin

AU - Angermeier, S

AU - Rumpold, H

AU - Ohler, L

AU - Gruenberger, B

AU - Niedersuess-Beke, D

AU - Winder, T

AU - Trojan, J

AU - Prager, GW

AU - Baraniskin, A

AU - Klein-Scory, S

PY - 2023/6/1

Y1 - 2023/6/1

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:001053772000712

M3 - Conference abstract

SN - 0732-183X

VL - 41

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

T2 - 59th Annual Meeting of the American Society of Clinical Oncology

Y2 - 2 June 2023 through 6 June 2023

ER -

Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.

Branches of science

Links

Activities

Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.

Cite this